NHS
Is this an Oppenheimer moment for the life sciences industry?
October 29, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate the magnitude of coordinated effort …
Turning a 10-Year Vision into a 10-Year Plan
October 27, 2025Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Population Health Management, Visions4Health, pharmacy
In the sixth of the Gateway to Local Adoption series, Visions4Health’s Head of Client Services, Jonny Savage, shares his views …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
October 8, 2025Medical Communications COVID-19, NHS, pharmacies, vaccinations
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments despite no longer meeting the …
From sickness to prevention: the case for population health management
October 3, 2025Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Population Health Management, Visions4Health, pharmacy
In the third of the Gateway to Local Adoption series, Visions4Health caught up with James Scott, Digital and Informatics Specialist …
From Vaccine Innovation Pathway to growth powerhouse: how the UK is transforming clinical trials
October 2, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing 10 Year Health Plan, Life Sciences Sector Plan, NHS, National Institute for Health and Care Research, Pharmacy, UK Vaccine Innovation Pathway
Commercial clinical trials are a high-value growth driver for a country’s health and the economy and a key component of …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
The UK’s Life Sciences Sector Plan: a fresh launchpad or a continued labyrinth for the uptake of innovative medicines?
August 27, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health
As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …
Single national formulary and community care: a closer look at the 10-Year Health Plan
August 21, 2025Business Services, Market Access Gateway to Local Adoption, NHS, Visions4Health
In the fourth of the Gateway to Local Adoption series, Visions4Health caught up with Frances Smith, Clinical Pharmacy Services Manager, …
Rollout of world-first gonorrhoea vaccine programme begins under NHS
August 8, 2025Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination
From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …
Sanome’s AI tool gains certification for early detection of hospital infections
August 7, 2025Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …
Key strategies to foster digital transformation in the NHS
July 30, 2025Business Services, Market Access, Market Access Consultancy Corporate, Gateway to Local Adoption, NHS, Pharmacy, Visions4Health, digital transformation, pharmacy
In the third of the Gateway to Local Adoption series, Visions4Health caught up with James Scott, Digital and Informatics Specialist …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
NICE recommends NHS use of mirikizumab for Crohn’s disease
July 11, 2025Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial
Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
The Problem of Endometriosis in the UK
July 7, 2025Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology
When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
